Hameln Pharma GmbH   Report issue

Contributed to NME For profit Phase 2
Founded: Hamelin Germany (1890)

Organization Overview

First Clinical Trial
2016
NCT02947022
First Marketed Drug
2004
diethylenetriaminepentaacetate
First NDA Approval
2004
diethylenetriaminepentaacetate
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

HAMELN | HAMELN PHARMA PLUS | HAMELN RDS GMBH

Active Ingredients

Marketed Drugs (2)

diethylenetriaminepentaacetate (2004 NDA)

gemcitabine (gemzar) (2012)

Drugs in Phase 2 Trials (2)

calcium (1 trial)

zinc dtpa (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthralgia (Phase 2)

Cognitive Dysfunction (Phase 2)

Headache (Phase 2)

Hyperpigmentation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2